Development of Pathogenesis and new drug that focuses on aggregate formation of Parkinson's disease

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K23782
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0704:Neuroscience, brain sciences, and related fields
• Research Institution: Juntendo University
• Principal Investigator: NODA Sachiko 順天堂大学, 医学部, 特任助手 (00846371)
• Project Period (FY): 2019-08-30 – 2021-03-31
• Keywords: パーキンソン病 / Atg7 / シャペロンタンパク / オートファジー

Outline of Final Research Achievements

Focusing on known chemically synthesized chaperones that are already known to be effective against humans, these drugs were administered to Parkinson's disease model mice to determine their in vivo aggregate inhibitory effect. No decrease was observed even when synthetic chapelone was administered to mice aged 5 weeks or older, and the results of time course measurement of the anti-aggregation effect revealed that the effect was saturated in 2 consecutive weeks.

Free Research Field

神経学

Academic Significance and Societal Importance of the Research Achievements

本研究は適正な高次構造の形成を補助する合成化学物質であるシャペロンタンパク質に着目し投与実験を行っており、マウスを使用した実験は新規性が高い。オートファジーの破綻によって形成された凝集体の神経細胞に対する毒性効果が立証されれば、凝集体形成抑制による神経保護治療研究に展開できる可能性がある。